Show simple item record

The combination of vemurafenib and cobimetinib in advanced melanoma

dc.contributor.authorSpain, L
dc.contributor.authorGoode, E
dc.contributor.authorMcGovern, Y
dc.contributor.authorJoshi, K
dc.contributor.authorLarkin, J
dc.date.accessioned2017-03-24T14:35:25Z
dc.date.issued2016-11-01
dc.identifierhttp://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000386809800003&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=d4b848928d1c3e5c86d298abb68475f9
dc.identifier.citationEXPERT OPINION ON ORPHAN DRUGS, 2016, 4 (11), pp. 1105 - 1111 (7)
dc.identifier.issn2167-8707
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/506
dc.identifier.doi10.1080/21678707.2016.1241707
dc.format.extent1105 - 1111 (7)
dc.languageeng
dc.language.isoeng
dc.publisherTAYLOR & FRANCIS LTD
dc.rights.urihttps://www.rioxx.net/licenses/all-rights-reserved
dc.subjectScience & Technology
dc.subjectLife Sciences & Biomedicine
dc.subjectPharmacology & Pharmacy
dc.subjectVemurafenib
dc.subjectcobimetinib
dc.subjectadvanced melanoma
dc.subjectBRAF mutation
dc.subjectMAPK pathway
dc.subjectBRAF-MUTATED MELANOMA
dc.subjectRANDOMIZED CONTROLLED-TRIAL
dc.subjectFREE SURVIVAL PFS
dc.subjectMETASTATIC MELANOMA
dc.subjectMEK INHIBITION
dc.subjectOPEN-LABEL
dc.subjectPOSITIVE MELANOMA
dc.subjectMUTANT MELANOMA
dc.subjectRAF INHIBITION
dc.subjectRESISTANCE
dc.titleThe combination of vemurafenib and cobimetinib in advanced melanoma
dc.typeJournal Article
rioxxterms.versionofrecord10.1080/21678707.2016.1241707
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2016-11-01
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfEXPERT OPINION ON ORPHAN DRUGS
pubs.issue11
pubs.notes12 months
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume4
pubs.embargo.terms12 months
icr.researchteamMelanoma and Kidney Cancer
dc.contributor.icrauthorGoode, Emily


Files in this item

Thumbnail
Name:
JL2 - The combination of vemur ...
Size:
1016.Kb
Format:
PDF
Description:
Accepted version
View/Open

This item appears in the following collection(s)

Show simple item record